Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Methotrexate in Diffuse Cutaneous Systemic Sclerosis
NCT06936215Phase 3Recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of baricitinib in diffuse cutaneous systemic sclerosis (dcSSc) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: modified Rodnan Skin Score at 24 weeks. Started Jan 2024; status: recruiting.
02
Drugs
baricitinib
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT06936215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936215.